Bicycle Therapeutics plc has released a corporate presentation detailing its development of Bicycle® molecules, a novel synthetic peptide modality designed to deliver various therapeutic payloads to disease targets. The presentation highlights ongoing internal programs focused on oncology, including clinical molecules such as zelenectide pevedotin for metastatic urothelial cancer and a novel gene amplification strategy for targeting additional cancers. The company is also advancing a radiopharmaceuticals pipeline addressing cancer targets like MT1-MMP and EphA2 and extending the use of its platform into therapeutic areas such as neurology. Bicycle® molecules are characterized by their small size, rapid tissue penetration, and high affinity for precision targeting, with the platform offering a modular toolkit for the creation of precision-guided medicines. The company reports cash and cash equivalents of $648.3 million as of September 30, 2025, with a projected financial runway into 2028. You can access the full presentation through the link below.